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tomy stroke rate of 1% to 10% in the immediate postop-
erative period,1 mostly due to thrombosis, and a resteno-
sis rate of 10% to 20% at 2 to 5 years postoperatively, most
of which is due to intimal hyperplasia.2 Thrombosis
develops when platelets bind to the exposed subendothe-
lial collagen by means of the von Willebrand factor and
become activated, thereby enhancing adhesion to other
platelets and encouraging thrombus formation. Intimal
hyperplasia development is initiated by the accumulation
of a monolayer of platelets. The adherence of platelets to
subendothelial collagen leads to their activation, their
degranulation, and the release of mitogenic and chemo-
tactic factors, which contribute to smooth muscle cell
activation followed by the development of intimal hyper-
plasia. In this study, we hypothesize that local interference
with the development of platelet adhesion to an exposed
collagen surface will decrease the subsequent develop-
ment of thrombosis and intimal hyperplasia after a rat
carotid endarterectomy.
Carotid endarterectomy may be complicated by the
development of thrombosis or intimal hyperplasia.
Clinical studies demonstrate a post–carotid endarterec-
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Purpose: Post–carotid endarterectomy, thrombosis, and intimal hyperplasia may be decreased by the inhibition of
platelet adhesion and activation. In this study, a novel agent, saratin, was used to inhibit platelet-to-collagen adhesion
in a rat carotid endarterectomy model. Saratin is a recombinant protein isolated from the saliva of the medicinal leech
Hirudo medicinalis, which is thought to act by binding to collagen, and inhibits von Willebrand factor–collagen inter-
action under conditions of increased shear and therefore, the adherence and activation of platelets at the vessel wall.
Saratin has the advantage of being a nonsystemic, site-specific topical application.
Methods: A rat carotid endarterectomy model was used in which an open technique with arteriotomy and intimectomy
was used. Saratin was applied to the endarterectomized surface of the carotid artery before arterial closure. End point
measurements included platelet adhesion, thrombosis rate, intimal hyperplasia development, bleeding times, and
platelet counts. Electron micrographs of carotid arteries were used for quantitative analysis of platelet aggregation and
platelet counts. Intimal hyperplasia and thrombosis were assessed with computer-assisted morphometric analysis of
elastin-stained carotid artery sections with direct measurement of the intimal hyperplasia area.
Results: The topical application of saratin significantly decreased platelet adhesion compared with controls at 3 hours
after carotid endarterectomy (64 ± 17 vs 155 ± 33 platelets per grid, P = .05), and 24 hours after carotid endarterec-
tomy (35 ± 11 vs 149 ± 37 platelets per grid, P = .0110), respectively. A percent luminal stenosis, as a measure of inti-
mal hyperplasia, was significantly decreased with saratin application compared with controls (10.9% ± 1.8% vs 29.8% ±
6.8%, P = .0042). This decrease in intimal hyperplasia formation correlated with the inhibition of platelet adhesion.
Thirty-three percent of control arteries were found to be thrombosed 2 weeks after carotid endarterectomy compared
with a 0% thrombosis rate in the saratin-treated group (P = .0156). No increased bleeding was encountered along the
arterial suture line in the saratin group. Bleeding times and systemic platelet counts were not found to change signifi-
cantly in the saratin-treated rats compared with control rats at 3 and 24 hours after endarterectomy.
Conclusion: Saratin significantly decreased platelet adhesion, intimal hyperplasia, luminal stenosis, and thrombosis after
carotid endarterectomy in rats. Saratin did not increase suture line bleeding or bleeding times, and did not decrease
platelet counts. Saratin may serve as a topical agent to be used for the site-specific inhibition of thrombosis and inti-
mal hyperplasia after vascular manipulation. (J Vasc Surg 2001;34:724-9.)
A rat carotid endarterectomy model that involved an
arteriotomy and direct removal of the intima/media layer
previously described by our group3 was used. Saratin, a
novel agent that has been suggested to inhibit platelet to
collagen adhesion through inhibition of von Willebrand
factor binding to collagen and that can be used in a site-
specific manner by way of topical administration directly
onto the endarterectomized surface, was used in this
model.
Saratin is a 12,000-d recombinant protein isolated
from the saliva of the medicinal leech Hirudo medicinalis
and is thought to block the adhesion of platelets to colla-
gen. Saratin’s proposed ability to affect the local environ-
ment of an endarterectomized vessel without requiring
systemic distribution and without altering platelet func-
tion or coagulation makes it ideal for topical application
during vascular surgical procedures.
MATERIALS AND METHODS
Animals. Sprague-Dawley rats (350-400 g) were
organized into carotid endarterectomy groups on the basis
of two main objectives: (1) evaluation of platelet adhesion
and (2) evaluation of lumen stenosis due to intimal hyper-
plasia, as well as thrombosis rate. Within these two objec-
tives, rats were divided into control and saratin-treated
animals. All rats underwent a carotid endarterectomy;
saratin-treated rats received a topical application of 5-µL
solution of saratin on the luminal surface of the carotid
artery immediately after endarterectomy. The platelet-
adhesion group was evaluated by means of electron
microscopy at 3 hours after carotid endarterectomy (n =
17) and 24 hours after carotid endarterectomy (n = 19).
The intimal hyperplasia and thrombosis groups (n = 25)
were harvested 2 weeks after carotid endarterectomy.
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Carotid endarterectomy operation. The operative
procedure has been previously described by our group3:
rats were anesthetized, and the right common carotid
artery was exposed. Arterial control was obtained and an
arteriotomy performed. The intima and media were
removed with microforceps, and the arteriotomy was
closed.
Platelet-adhesion group. In the platelet-adhesion
subgroups, the rats were reanesthetized, and the
endarterectomized carotid arteries were harvested and
fixed in a 4% glutaldehyde solution at 3 hours or 24 hours
after carotid endarterectomy. The arteries were postfixed
with osmium tetroxide, dehydrated in a graded alcohol
series, dried by critical point with carbon dioxide (1072
psi and 31.1°C), coated with gold palladium, and placed
in the scanning electron microscope (JEOL JSM 5410;
JEOL, USA, Peabody, Mass). The endarterectomized
areas were scanned at 2000× magnification and pho-
tographed. A collage of photographs was assembled and
covered with a transparent overlay grid that consisted of
116 squares that were used to count the total number of
platelets in each photograph. Platelet counts were per-
formed by two blinded observers.
Intimal hyperplasia group. At 2 weeks after carotid
endarterectomy, rats in the intimal hyperplasia and throm-
bosis groups were anesthetized, and the endarterec-
tomized carotid artery was exposed. The vena cava was
transected and the distal aorta cannulated with a 20-gauge
catheter to infuse normal saline at 100 mm Hg until the
vena cava effluent ran clear. Next, 10% buffered formalin
was infused at 100 mm Hg in an equal volume to com-
plete the perfusion-fixation technique. A 1-cm section of
the operated carotid artery was dissected and placed in
10% formalin. The arteries were blocked with paraffin,
Fig 1. Number of platelets adherent to exposed subendothelial
surface 3 hours after carotid endarterectomy, comparing saratin-
treated group (n = 7) and control group (n = 10). Data are means
± SE. Platelets were counted with scanning electron microscope.
Saratin group received 5 µL of saratin solution applied topically
to exposed subendothelial surface. Star indicates P value of .05.
Fig 2. Number of platelets adherent to exposed subendothelial
surface 24 hours after carotid endarterectomy comparing saratin-
treated group (n = 9) and control group (n = 10). Data are means
± SE. Platelets were counted with scanning electron microscope.
Saratin group received 5 µL of saratin solution applied topically
to exposed subendothelial surface. Star indicates P value of .01.
sectioned, and elastin stained with Verhoeff ’s and van
Gieson’s stain. Multiple sections were taken at intervals of
3 µm each continuing along the distance of the continu-
ous 10-0 nylon suture arteriotomy closure to standardize
the region of sectioning. The elastin-stained slides were
photographed with a Kodak DC 120 Zoom digital camera
(Eastman Kodak Company, Rochester, NY). Any throm-
bosed sections were noted at this time. Nonthrombosed
images were downloaded into a computer, and the lumi-
nal areas of the carotids were analyzed with the National
Institutes of Health (Bethesda, Md) ImageJ Software pro-
gram, Version 0.99i. This software package allowed us to
delineate the inner area of the intimal hyperplasia and thus
obtain an accurate measure of the cross-sectional area of
the vessel lumen. The characteristic pattern of intimal
hyperplasia was used to identify the demarcation between
the outer limits of intimal hyperplasia and the
medial/adventitial layers. The difference between the two
areas (outer area of intimal hyperplasia minus the actual
lumen) was determined as the absolute area of intimal
hyperplasia. Because the arterial cross section had individ-
ual variations of shape, the values were expressed as a ratio
of the absolute area of intimal hyperplasia to the outer
limit of intimal hyperplasia and was reported as a percent
lumen stenosis. This ratio represents the proportion of the
lumen area occupied by intimal hyperplasia and allowed
for comparison of the arterial cross sections of varying
size.4 Minimal variability was seen between measurements
with two blinded observers.
Bleeding times and platelet counts. Platelet counts
and bleeding times of 12 rats were determined. All rats
had platelet counts and bleeding times preoperatively. Six
rats underwent a carotid endarterectomy and were har-
vested 3 hours postoperatively with bleeding times and
platelet counts measured, and the remaining six rats were
harvested 24 hours postoperatively with bleeding times
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and platelet counts measured. Three of the rats in each
time group received topical saratin, and the remaining
three rats served as controls.
Bleeding times were determined by transecting the
distal 2 mm of the rat’s tail and submerging 4 cm of the
tail into a solution of phosphate-buffered solution at
37°C. The amount of time that elapsed from tail transec-
tion to cessation of bleeding was measured and was
assigned as the bleeding time. Platelet counts were deter-
mined by drawing a 1- to 1.5-cc sample of blood from the
internal jugular vein, which was analyzed in a Coulter
STKS blood analyzer (Brea, Calif), and the results were
expressed ×103. For the assessment of saratin’s effect on
platelet counts, the difference in platelet counts was deter-
mined for each rat by subtracting the preoperative platelet
count from the postoperative platelet count to obtain a
difference score.
This study was approved by the Institutional Review
Board. All animal care complied with the Guide for the Care
and Use of Laboratory Animals, Institute of Laboratory
Animal Resources, Commission on Life Sciences, National
Research Council. Washington: National Academy Press,
1996.
Statistical methods. Please see the Appendix (online
only) for details about statistical methods.
RESULTS
The topical application of saratin onto exposed suben-
dothelium after carotid endarterectomy significantly
decreases the number of adherent platelets. The antiplatelet
adherence effect of saratin was evaluated after two different
postoperative times, 3 hours and 24 hours. The difference
in the number of adherent platelets at 3 hours (Fig 1) and
24 hours (Fig 2) after carotid endarterectomy was signifi-
cantly reduced in the rats treated with saratin as compared
with the control rats. Platelet adhesion was reduced by 59%
Fig 3. Electron micrograph (2000×) of endarterectomized rat
carotid artery 3 hours after carotid endarterectomy. A, Control
surface. B, Surface receiving topical saratin (5 µL). Control sur-
face shows abundant cellular elements including fibrin strands,
red blood cells, and platelets. Saratin-treated surface shows
marked decrease in cellular elements.
Fig 4. Electron micrograph (2000×) of endarterectomized rat
carotid artery 24 hours after carotid endarterectomy. A, Control
surface. B, Surface receiving topical saratin (5 µL). Control sur-
face shows numerous red blood cells and platelets. Saratin-
treated surface shows marked decrease in platelet adhesion.
at 3 hours (P = .05) and 77% at 24 hours (P = .011).
Platelet adhesion was similar at 3 hours and 24 hours in the
control groups but did show a decrease in the saratin-
treated group from 64 to 35 platelets per grid, although
this was not statistically significant.
Figs 3 and 4 show a typical representation of the
endarterectomized surface with and without topical
saratin with scanning electron microscopy at 2000× mag-
nification. Fig 3, A, shows the control surface at 3 hours
after carotid endarterectomy; note the abundance of cel-
lular material, fibrin strands, numerous red blood cells,
and numerous platelets. Fig 3, B, shows a saratin-treated
surface 3 hours after carotid endarterectomy. Note the
lack of cellular elements and the near barren collagen sur-
face. Fig 4, A, shows a control surface at 24 hours after
carotid endarterectomy; platelets are evident as small
white dots. Fig 4, B, is a saratin-treated surface at 24 hours
after carotid endarterectomy. There is a reduction in
platelet adhesion with saratin treatment with the exposed
damaged collagen surface evident.
The application of topical saratin after a carotid
endarterectomy significantly decreased the development
of intimal hyperplasia as compared with the control group.
In terms of luminal stenosis, control rats showed a 29.8%
luminal stenosis versus a 10.9% luminal stenosis in the
saratin-treated group (Fig 5). Saratin-treated rats had
18.9% greater luminal diameter than control rats. At 2
weeks afer carotid endarterectomy, five (33%) of the 15
control rats had complete thrombosis of the carotid artery
on histologic analysis, whereas none (0%) of the 15
saratin-treated rats had thrombosis. A likelihood ratio–χ2
analysis revealed an odds ratio of 16.238, which suggests
that the odds of the control group having occlusive
thrombosis was 16 times greater than the rats treated with
saratin (P = .0156). No increased suture-line bleeding was
noted in the saratin-treated group.
For platelet counts to be determined, it was necessary
to obtain a preoperative blood sample from each rat of
approximately 1- to 1.5-cc, which represents a significant
portion of a rat’s total blood volume. In view of this, it is
reasonable to expect a decrease in the postoperative
platelet counts of both control and saratin rats. The dif-
ference between preoperative and postoperative platelet
counts was compared for the control and saratin-treated
groups. No statistical significance in the platelet count dif-
ferences between control and saratin-treated rats was
noted. No statistically significant differences were
observed between preoperative and postoperative bleed-
ing times.
DISCUSSION
Carotid endarterectomy is one of the most common
vascular surgical procedures performed in the United
States. Results from multicenter trials have demonstrated
the efficacy of this procedure in the treatment of extracra-
nial carotid disease in patients both with and without
symptoms.5,6 Endarterectomy procedures are used in the
treatment of occlusive vascular disease in other vascular
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beds.7 Endarterectomy leaves a significant area of throm-
bogenic subendothelium exposed. Despite the efficacy of
carotid endarterectomy, the operation can lead to compli-
cations, including thrombosis and the development of
intimal hyperplasia. Platelet accumulation may occur at
the endarterectomy site. Clinical studies have demon-
strated a post–carotid endarterectomy stroke rate of 1% to
10% in the immediate postoperative period, most of which
is accounted for by thrombus formation with subsequent
cerebral embolization.1 Platelet accumulation may also
result in restenosis due to intimal hyperplasia. Restenosis
has been reported to occur in 10% to 20% of endarterec-
tomized patients at 2 to 5 years postoperatively, most of
which is due to intimal hyperplasia, intimal thickening,
and vessel diameter reduction.2 In the current study we
have demonstrated a significant reduction in platelet adhe-
sion after carotid endarterectomy that is associated with
the clinically relevant finding of reduced intimal hyperpla-
sia. Saratin-treated rats showed only 25% of the intimal
hyperplasia observed in control rats.
Intimal hyperplasia development involves medial
smooth muscle cell proliferation, migration into the
intima, and finally proliferation and production of extra-
cellular matrix.8 Studies in which endarterectomized rat
carotid artery models9 and embolectomy balloon-injury
models10 have been used have shown that as the endothe-
lial cells are stripped away during vascular injury, platelets
begin to adhere to the exposed subendothelium. Spallone
et al,9 using scanning electron microscopy, have shown
that 5 minutes after a carotid endarterectomy in a rat, a
monolayer of platelets is formed over the injured area.
Fifteen minutes after the injury, platelet aggregation and
thrombus formation are observed. Thirty minutes after
endarterectomy, the site is covered with activated platelets
Fig 5. Percent luminal stenosis resulting from intimal hyperpla-
sia 2 weeks after carotid endarterectomy. Saratin-treated group (n
= 15) and control group (n = 10) are shown. Saratin group
received 5 µL of saratin applied topically to exposed subendothe-
lial surface. Star indicates P value of .004.
and coated by fibrin and red blood cells. Thrombus for-
mation reaches its peak at 3 hours after injury, with a thick
fibrin-platelet layer being observed. Platelets are an inte-
gral component of this thrombus formation and thus
thrombosis, but they also appear to play a role in the
development of intimal hyperplasia. Studies in which
thrombocytopenic rats have been used have demonstrated
a significant decrease in intimal thickening after carotid
artery injury as compared with control rats.11 Once
platelets adhere to the exposed subendothelium of an
injured vessel, they become activated and release their
granules. These granules contain vasoactive and throm-
botic factors (serotonin, adenosine diphosphate, fibrino-
gen, von Willebrand factor, thromboxane A2), as well as
growth factors (platelet-derived growth factor, transform-
ing growth factor-β, and epidermal growth factor).12 The
exact mechanisms by which platelets enhance the develop-
ment of intimal hyperplasia are not yet completely under-
stood. Studies suggest that platelets provide primarily a
chemotactic stimulus for medial smooth muscle cell
migration toward the intima during the second phase of
intimal hyperplasia development.13 Other studies, in
which anti–platelet-derived growth factor antibodies were
used, have demonstrated the vital role that platelet-
derived growth factor plays in neointimal smooth muscle
cell accumulation after a vascular injury.14 Another mech-
anism by which platelets may enhance the development of
intimal hyperplasia is through the activation of the coagu-
lation cascade and the subsequent accumulation of throm-
bin at the site of injury. Several studies have demonstrated
the mitogenic effects of thrombin on smooth muscle
cells.15,16 In addition, thrombin has been shown to be a
stimulus for platelet activation.17 Regardless of the precise
mechanism, platelet adhesion and activation at the site of
a vascular injury play a significant role in the development
of thrombosis and intimal hyperplasia, and therefore, inhi-
bition of platelet adhesion and activation may help prevent
or reduce thrombosis rates and intimal hyperplasia devel-
opment. An ideal agent for the attenuation of the intimal
hyperplasia response would be one that produces site-
specific and localized antiplatelet effects without systemic
distribution or a generalized coagulopathy.
It appears that the vital steps that precipitate the cas-
cade of events leading to thrombosis and later intimal
hyperplasia stem from the interaction between the
exposed subendothelial collagen at the site of vessel injury
and a monolayer of platelets that adhere to the exposed
collagen. A specific inhibitor of this platelet to suben-
dothelial collagen adhesion may serve to prevent or at least
decrease the development of thrombus and intimal hyper-
plasia. This study was designed to examine one such agent.
The novel aspect of the study is the use of a topical agent
at the site of injury with the potential of decreasing throm-
bosis, intimal hyperplasia, or both without any systemic
effects. A rat carotid endarterectomy model was used that
is reliable and reproducible and that mimics a human
carotid endarterectomy to a closer extent than the bal-
loon-injury model.3 We think that the use of a direct arte-
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riotomy and suture closure is crucial for evaluation of an
agent that may lead to a reduction in localized hemostatic
mechanisms.
Studies with hematophagous organisms have shown
that salivary secretions from various leeches have
antiplatelet properties. Leech antiplatelet protein, a pro-
tein of approximately 16,000-d from the leech
Haementeria officinalis has been shown to inhibit colla-
gen-induced platelet aggregation and adhesion, as has
Calin, a 65,000-d protein from H medicinalis,18,19 and
leech antiplatelet protein and Calin have been shown to
inhibit von Willebrand factor binding to collagen.20,21
However, in the most pathophysiologically relevant situa-
tions (mechanical damage to the arterial wall, plaque rup-
ture), platelet adhesion through collagen–von Willebrand
factor interaction is thought to be crucial in the initial
tethering of platelets (through platelet glycoprotein
Ib/IX/V receptors). Therefore, focused inhibition of
platelet adhesion through collagen–von Willebrand factor
binding, with little or no effect on platelet aggregation,
might result in a more localized, injury-specific
antithrombotic response, without general systemic
antiplatelet effects. Thus, the saliva of H medicinalis was
analyzed for the existence of a selective inhibitor of colla-
gen–von Willebrand factor binding. Indeed, a protein of
relatively low molecular weight (approximately 12,000 d),
whose primary mechanism of action is thought to be inhi-
bition of von Willebrand factor binding to collagen at high
shear and which has no effect on platelet aggregation at
these concentrations, has been isolated and named
saratin. This saratin-mediated inhibition of initial platelet
adhesion under elevated shear may result in a decreased
thrombosis rate and a decrease in the development of inti-
mal hyperplasia. This represents a modality with specific
and localized effects, well suited for application by both
surgeons and interventional radiologists.
We have shown a significant decrease in platelet adhe-
sion and accumulation after a vascular injury similar to
endarterectomy. The decreased platelet adhesion is seen
both immediately after endarterectomy (3 hours) as well
as at 24 hours. The effect at 24 hours is significant in that
we think this effect is not due to the direct inhibitory
effect of saratin on the collagen; rather, it is due to the ini-
tial inhibition of platelet aggregation and the subsequent
disruption of the platelet activation cascade. Once platelets
are initially inhibited from attaching to exposed collagen,
the platelet cascade cannot proceed. Figs 1 and 2 demon-
strate that the topical application of saratin on the recently
injured vessel can inhibit platelet adhesion to a significant
degree. Saratin inhibited platelet adhesion by 59% and
77% at 3 and 24 hours, respectively. This inhibition is
noted in the visible differences in cellular element deposi-
tion between control and saratin-treated arteries at both 3
hours and 24 hours (Figs 4 and 5). We propose that this
lack of cellular response is due to the inhibition of platelet
adhesion. This represents a unique mode of therapy for
the inhibition of platelet adhesion to an injured vessel.
Control rats had a significantly reduced luminal diameter
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at 2 weeks after carotid endarterectomy compared with
saratin-treated rats. The amount of intimal hyperplasia
development was significantly reduced in saratin-treated
rats, which correlated with reduced platelet adhesion and
accumulation. The finding of decreased intimal hyperpla-
sia and thrombosis provides for clinically relevant end
points and sequelae of reduced platelet adhesion. This
suggests that the site-specific, nonsystemic inhibition of
platelet aggregation and adhesion can lead to a decreased
thrombosis and occlusion rate and possibly reduce the
incidence of cerebrovascular events that occurred after
carotid endarterectomy. The degree or level of intimal
hyperplasia and luminal stenosis improvement may be
arguable; however, the significant finding of a decreased
thrombosis rate in rats treated with saratin is relevant. A
full 33% of control rats showed thrombosis, whereas none
of the saratin-treated carotid arteries were thrombosed. Of
particular clinical importance is the lack of systemic effects
demonstrated by this agent. The local application of
saratin did not affect systemic bleeding times or platelet
counts when compared with controls. This implies that
the decreased platelet adhesion and the subsequent
decrease in thrombosis and intimal hyperplasia are the
result of local effects. These findings are encouraging and
elicit a cautious degree of excitement in that the spectrum
of clinical applications for a modality that is capable of
locally inhibiting the deleterious effects of platelet adhe-
sion and activation without disturbing the systemic hemo-
static mechanism is vast.
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